Clinicopathological analysis based on the TCGA-PAAD cohort and our PAAD verification cohorts revealed that PLAGL1 was negatively correlated with the Ki67+ cell rate and pathologic stage, indicating that PLAGL1 might suppress the growth of PAAD. This evidence concerns the gene PLAGL1 and pancreatic adenocarcinoma.